Pacira BioSciences' Equity Average fell 8.83% to $742.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $742.5 million, marking a year-over-year decrease of 8.83%. This contributed to the annual value of $824.2 million for FY2024, which is 0.20% up from last year.
Latest data reveals that Pacira BioSciences reported Equity Average of $742.5 million as of Q3 2025, which was down 4.58% from $778.2 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Equity Average ranged from a high of $885.7 million in Q2 2024 and a low of $635.3 million during Q1 2021.
Moreover, its 3-year median value for Equity Average was $788.4 million (2025), whereas its average is $807.7 million.
Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 75.55% in 2021, then dropped by 12.14% in 2025.
Over the past 5 years, Pacira BioSciences' Equity Average (Quarterly) stood at $724.5 million in 2021, then increased by 6.63% to $772.6 million in 2022, then climbed by 10.13% to $850.8 million in 2023, then declined by 10.21% to $764.0 million in 2024, then fell by 8.83% to $742.5 million in 2025.
Its Equity Average was $742.5 million in Q3 2025, compared to $778.2 million in Q2 2025 and $788.4 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value